Monitor for the actual conversion of Series A Preferred Stock into common shares, which will increase the outstanding share count. The conversion was approved on October 28, 2026 and should occur within three business days.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 2 $3.89entry
- T+1 · 14d ago +6.68%α +6.38% · $4.15
- T+5 · 8d ago +4.11%α +4.03% · $4.05
- T+11 · todayOpen
- T+20 · in 14d Pending
- T+60 · in 2mo Pending
Price Chart
How similar events traded
Executive Summary
Julie Saiki filed a Form 3 initial statement of beneficial ownership after becoming Chief Strategy Officer of Adial Pharmaceuticals. The filing discloses her holdings including common stock, stock options, and Series A Preferred Stock convertible into 1,852,229 common shares, reflecting her role following the company's merger with Azora Therapeutics. This is a routine insider ownership disclosure with no immediate trading signal.
Key Facts
- Julie Saiki appointed Chief Strategy Officer of Adial Pharmaceuticals, Inc.
- Form 3 filed on 2026-10-30, reporting period 2026-10-28.
- Directly holds 72,719 shares of common stock and 62,665 shares indirectly.
- Holds stock options to buy 72,719 shares at $2.98, 31,915 at $1.57, and 67,021 at $0.63.
- Holds Series A Preferred Stock convertible into 1,852,229 common shares (1,000:1 conversion ratio).
- Series A Preferred Stock conversion approved by stockholders on 2026-10-28, conversion automatic within 3 business days.
- Holdings stem from the June 11, 2026 merger with Azora Therapeutics, Inc.
Financial Impact
No financial impact from this filing. The Series A Preferred Stock conversion (1,852,229 common shares) was previously approved and is a post-merger event.
Risk Factors
- Potential dilution from conversion of Series A Preferred Stock into 1,852,229 common shares.
- Insider selling risk if Saiki exercises options and sells shares post-conversion.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001213900-26-114578 |
| Document: 0001213900-26-114578-index-headers.html | 0001213900-26-114578 |
| Document: 0001213900-26-114578-index.html | 0001213900-26-114578 |
| Document: 0001213900-26-114578.txt | 0001213900-26-114578 |
Track record
23 reports on ADIL
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +138.93% at T+60 after the Jun 11, 2026 report. 5 of 10 went positive at some point.
Filters
- Nov 12, 20265d ago Press Release Neutral 4/10 No price data
- Oct 30, 202617d ago 3 Neutral 2/10 Viewing Entry $3.89 settles Jan 29
- Oct 30, 202617d ago 3 Neutral 2/10 Entry $3.89 settles Jan 29
- Oct 28, 202620d ago 8-K Neutral 5/10 Entry $4.88 settles Jan 27
- Oct 28, 202620d ago Press Release Neutral 5/10 Entry $4.88 settles Jan 27
- Oct 27, 202621d ago EFFECT Bearish 6/10 Entry $3.71 settles Jan 25
- Oct 20, 202627d ago 10-Q/A Bearish 7/10 Entry $4.11 settles Jan 19
- Oct 20, 202627d ago S-3/A Bearish 7/10 Entry $4.11 settles Jan 19
- Oct 16, 20264w ago DEFA14A Bearish 5/10 Entry $3.62 settles Jan 14
- Oct 16, 20264w ago 8-K Bearish 5/10 Entry $3.62 settles Jan 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers